Skip to main content

Table 4 Risk (%) of adverse events (of moderate or greater severity) associated with study treatment within the first 42 days of treatmentΔ

From: Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children

Adverse events

AQ+SP (n = 396)

AS+AQ (n = 362)

AL (n = 362)

Coryza

10.0%

12.2%

13.1%

Cough

14.7%

22.8%

20.9%

Anorexia*

10.3%

9.7%

5.5%

Weakness†

9.7%

6.5%

3.1%

Abdominal pain

6.0%

3.3%

3.4%

Vomiting

3.8%

1.7%

1.9%

Subjective fever

24.9%

22.8%

24.2%

Headache

1.5%

2.8%

3.4%

Rash

6.0%

5.5%

4.7%

Generalized pruritus

7.4%

8.2%

6.5%

Diarrhoea‡

0.7%

1.1%

3.2%

Elevated temperatureγ

4.8%

4.5%

9.2%

Nausea

1.0%

0.3%

0.3%

Hepatosplenomegaly

0.3%

0.3%

0.3%

  1. ΔRisk estimated by Kaplan-Meier product limit formula
  2. * Anorexia: AQ+SP vs. AL, p = 0.005
  3. † Weakness: AQ+SP vs. AL, p < 0.001
  4. ‡ Diarrhoea: AL vs. AQ+SP, p = 0.021
  5. γ Elevated Temperature: AL vs. AQ+SP, p = 0.029; AL vs. AS+AQ, p = 0.008